Edesa Biotech Advances EB06 Anti-CXCL10 Antibody Toward Phase 2 Vitiligo Trial in Mid-2026
核心洞察
Edesa Biotech is preparing to initiate a Phase 2 trial of EB06, an anti-CXCL10 (搜索) monoclonal antibody, for moderate-to-severe non-segmental vitiligo (搜索) patients by mid-2026.
The planned study will enroll approximately 160 patients and evaluate three different doses of EB06 administered intravenously every two weeks for up to 24 weeks.
With only one FDA-approved vitiligo (搜索) treatment carrying a black-box warning, EB06 addresses a significant unmet medical need in a market projected to reach $1.1 billion by 2030.
Edesa Biotech, Inc. (NASDAQ:EDSA) is preparing to advance its anti-CXCL10 (搜索) monoclonal antibody EB06 into a Phase 2 clinical trial for moderate-to-severe non-segmental vitiligo (搜索) patients, with enrollment anticipated to begin by mid-2026. The company has already received approval from Health Canada to conduct the Phase 2 trial and has initiated manufacturing activities to supply drug product for the study.
Targeting CXCL10 in Vitiligo Pathogenesis
Vitiligo (搜索) is an autoimmune disease that causes areas of the skin to lose color when pigment-producing cells (melanocytes) die or stop producing melanin. Non-segmental vitiligo is characterized by patches appearing on both sides of the body and can result from autoimmune disease, genetics, or triggering events such as stress, sunburn, or skin trauma.
Research has demonstrated that the chemokine CXCL10 (搜索) is elevated in both vitiligo (搜索) patient skin and serum. In a mouse model of vitiligo that includes CXCL10 expression in the skin, neutralization of CXCL10 in mice with established, widespread depigmentation induced reversal of disease as shown by repigmentation. Additionally, serum CXCL10 levels are significantly increased in vitiligo patients compared to controls, suggesting that CXCL10 may play a role in the pathogenesis of vitiligo in humans.
Phase 2 Trial Design and Timeline
The planned Phase 2 study will enroll approximately 160 patients with severe nonsegmental vitiligo (搜索) and will evaluate three different doses of EB06: 2.5 mg/kg, 5 mg/kg, and 10 mg/kg administered intravenously every two weeks for up to 24 weeks, followed by a 12-week follow-up period. The primary efficacy outcome will be the percentage of patients that achieve ≥50% decrease from baseline in facial Vitiligo Area Scoring Index (F-VASI50), a composite measurement of the overall area of facial vitiligo patches and degree of depigmentation within patches.
Edesa is currently preparing an IND submission for EB06 and has begun outreach to potential investigators. The final trial protocol will be contingent on feedback from the FDA, with enrollment initiation anticipated in mid-2026, dependent upon completion of manufacturing and regulatory activities.
Market Opportunity and Unmet Medical Need
The estimated prevalence of vitiligo (搜索) patients in the U.S. is between 1.9 million and 2.8 million, according to a 2022 publication. This corresponds to a vitiligo market that is projected to reach approximately $1.1 billion by 2030. Currently, the only FDA-approved therapy is topical ruxolitinib (Opzelura®), which generated approximately $500 million in revenue in 2024, with approximately $200 million of that coming from sales for vitiligo.
Importantly, Opzelura carries a black-box warning due to the potential for serious infections, major adverse cardiovascular events, and thrombosis. This safety concern highlights the clear unmet need for additional safe and effective treatment options for vitiligo (搜索) patients.
Positive Phase 3 Results for Respiratory Program
In October 2025, Edesa announced positive results from a Phase 3 trial evaluating paridiprubart (EB05) in the treatment of acute respiratory distress syndrome (搜索) (ARDS (搜索)). The Phase 3 trial enrolled 104 patients hospitalized in the ICU, receiving invasive mechanical ventilation, and had a positive SARS-CoV-2 test.
The study met the primary endpoint by showing a statistically significant improvement in 28-day mortality for patients treated with standard of care plus EB05 compared to those receiving only standard of care (P<0.001). The relative reduction in the risk of death at Day 28 was 25% for EB05-treated patients compared to placebo. A durable survival benefit was demonstrated as the relative reduction in the risk of death at Day 60 was 22% for EB05-treated patients compared to placebo.
Treatment with EB05 also led to significant improvement in clinical outcomes, with 38% of EB05-treated patients showing at least a 2-point reduction in the WHO 9-point ordinal scale compared to only 27% receiving standard of care (P=0.032). EB05 exhibited a favorable safety profile with no treatment-related adverse events observed in the 278 patients in the safety database.
Financial Position and Strategic Outlook
For fiscal year 2025 ended September 30, 2025, Edesa reported R&D expenses of $3.7 million, compared to $2.9 million for fiscal year 2024. The increase was primarily due to increased expenses for manufacturing-related activities and preparations for the planned Phase 2 clinical study of EB06 in vitiligo (搜索), along with expenses related to completion of the Phase 3 study of EB05.
As of September 30, 2025, Edesa had approximately $10.8 million in cash and cash equivalents. Subsequent to the fiscal year end, the company received $3.4 million in net proceeds from the sale of stock under its at-the-market offering program. As of December 12, 2025, the company had approximately 8.3 million common shares outstanding.
"Our strategy to advance a high-impact dermatology asset alongside a now-validated respiratory therapeutic is bearing fruit, and we believe Edesa is well positioned for our mission to deliver transformative therapies to patients with high unmet medical needs," said Par Nijhawan, MD, Chief Executive Officer of Edesa. The company is currently exploring development and commercialization partnerships for paridiprubart as well as expedited regulatory pathways that may be available in certain jurisdictions.